Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion

Journal of Molecular Biology

Volumn 330, Issue 5, 2003, Pages 1101-1115

  Barbato, Gaetano ^a   Bianchi, Elisabetta ^a   Ingallinella, Paolo ^a   Hurni, William H ^b   Miller, Michael D ^b   Ciliberto, Gennaro ^a   Cortese, Riccardo ^a   Bazzo, Renzo ^a   Shiver, John W ^b   Pessi, Antonello ^a  

^a IRBM   (Italy)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

2F5 epitope; gp41; HIV 1 fusion; NMR spectroscopy; Statistical conformational analysis

Indexed keywords

AMINO ACID; EPITOPE; HEXAPEPTIDE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN;

AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ANTIGEN STRUCTURE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STABILITY; STATISTICAL ANALYSIS; STRUCTURE ANALYSIS; VIRUS CELL INTERACTION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0038351790     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2836(03)00611-9     Document Type: Article

References (59)

1. Eckert D.M., Kim P.S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70:2001;777-810.
2. Freed E.O., Martin M.A. The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J. Biol. Chem. 270:1995;23883-23886.
3. Luciw P.A. Human immunodeficiency viruses and their replication. Nipe B.N., Howley P.M. Fields Virology. 3rd edit. 1996;1881-1952 Lippincott-Raven Publishers, Philadelphia.
4. Durell S.R., Martin I., Ruysschaert J.M., Shai Y., Blumenthal R. What studies of fusion peptides tell us about viral envelope glycoprotein-mediated membrane fusion. Mol. Membr. Biol. 14:1997;97-112.
5. Pecheur E.I., Sainte-Marie J., Bienvenue A., Hoekstra D. Peptides and membrane fusion: towards an understanding of the molecular mechanism of protein-induced fusion. J. Membr. Biol. 167:1999;1-17.
6. Weissenhorn W., Dessen A., Harrison S.C., Skehel J.J., Wiley D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature. 387:1997;426-430.
7. Chan D.C., Kim P.S. HIV entry and its inhibition. Cell. 93:1998;681-684.
8. Montefiori D.C. HIV-specific neutralizing antibodies. Pantaleo G., Walker B.D. Retroviral Immunology: Immune Response and Restoration. 2001;191-211 Humana Press, Totowa, NJ.
9. Trkola A., Pomales A.P., Yuan H., Korber B., Maddon P.J., Allaway G., et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:1995;6609-6617.
10. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:1993;6642-6647.
11. Purtscher M., Trkola A., Grassauer A., Schulz P.M., Klima A., Döpper S., et al. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS. 10:1996;587-593.
12. Zwick M.B., Labrjin A.K., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75:2001;10892-10905.
13. Conley A.J., Kessler J.A. II, Boots L.J., Tung J.-S., Arnold B.A., Keller P.M., et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl Acad. Sci. USA. 91:1994;3348-3352.
14. D'Souza M.P., Livnat D., Bradac J.A., Bridges S. Evaluation of monoclonal antibodies to HIV-1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. J. Infect. Dis. 175:1997;1056-1062.
15. Mascola J.R., Lewis M.G., Stiegler R., Harris D., VanCott D.C., Hayes D., et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:1999;4009-4018.
16. Baba T.H., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nature Med. 6:2000;200-206.
17. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Med. 6:2000;207-210.
18. Armbruster C., Stiegler G.M., Vcelar B.A., Jager W., Michael N.L., Vetter N., Katinger H. A Phase I trial with two monoclonal antibodies (hmAb 2F5, 2G12) against HIV-1. AIDS. 16:2002;227-233.
19. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., et al. Generation of human monoclonal antibodies against HIV-1 proteins: electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses. 10:1994;359-369.
20. Purtscher M., Trkola A., Gruber G., Buchacher A., Predl R., Steindl F., et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses. 10:1994;1651-1658.
21. Muster T., Guinea R., Trkola A., Purtscher M., Klima A., Steindl F., Palese P. Cross-neutralizing activity against divergent human immunodeficiency virus Type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 68:1994;4031-4034.
22. Eckart L., Raffelsberger W., Ferko B., Purtscher K.A., Katinger H., Ruker F. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus Type 1 on recombinant surface antigen of hepatitis B virus. J. Gen. Virol. 77:1996;2001-2008.
23. Liang X., Munshi S., Shendure J., Mark G. III, Davies M.E., Freed D.C., et al. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope proteins. Vaccine. 17:1999;2862-2872.
24. Coëffier E., Clément J.M., Cussac V., Khodaie-Boorane N., Jehanno M., Rojas M., et al. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine. 19:2000;684-693.
25. Lu Y., Xiao Y., Ding J., Dierich M.P., Chen Y.-H. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein. Scand. J. Immunol. 51:2000;497-501.
26. Tian H., Xiao Y., Zhu M., Chen Y.-H. HIV epitope-peptides in aluminium adjuvant induced high levels of epitope-specific antibodies. Int. Immunopharm. 1:2001;763-768.
27. Poumbourios P., El Ahmar W., McPhee D.A., Kemp B.E. Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure. J. Virol. 69:1995;1209-1218.
28. Salzwedel K., West J.T., Hunter E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for env-mediated fusion and virus infectivity. J. Virol. 73:1999;2469-2480.
29. Kilby M.J., Hopkins S., Venetta T.M., DiMassimo B., Cloud G.A., Lee J.Y., et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med. 4:1998;1302-1307.
30. Lawless M.K., Barney S., Guthrie K.I., Bucy T.B., Bucy T.B., Petteway S.R., Merkuta G. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Biochemistry. 35:1996;13697-13708.
31. Suarez T., Gallaher R., Agirre A., Goni F.M., Nieva J.L. Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycoprotein: putative role during viral fusion. J. Virol. 74:2000;8038-8047.
32. Suarez T., Nir S., Goni F.M., Saez-Cirion A., Nieva J.L. The pre-transmembrane region of the human immunodeficiency virus type-1 glycoprotein: a novel fusogenic sequence. FEBS Letters. 477:2000;145-149.
33. Chan D.C., Fass D., Berger J.M., Kim P.S. Core structure of gp41 from HIV envelope glycoprotein. Cell. 89:1997;263-273.
34. Tan K., Liu J.-H., Wang J.-H., Shen S., Lu M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl Acad. Sci. USA. 94:1997;12303-12308.
35. Caffrey M., Cai M., Kaufman M., Stahl S.J., Wingfield P.T., Covell D.G., et al. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J. 17:1998;4572-4584.
36. Shibli D.J., Montelaro R.C., Vogel H.J. The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well defined helix in dodecylphosphocholine micelles. Biochemistry. 40:2001;9570-9578.
37. 10-helix is formed in water by a 13-residue peptide representing the neutralizing determinant of HIV-1 on gp41. Biochemistry. 41:2002;12687-12696.
38. Gallagher W.R., Ball J.M., Garry R.F., Griffin M.C., Montelaro R.C. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res. Hum. Retroviruses. 5:1989;431-440.
39. Joyce J.G., Hurni W.M., Bogusky M.J., Garsky V.M., Liang X., Danzeisen R.C., et al. Enhancement of α-helicity in the HIV-1 inhibitory peptide DP-178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro: implications for vaccine design. J. Biol. Chem. 277:2002;45811-45820.
40. Cicero D.O., Barbato G., Bazzo R. NMR analyisis of molecular flexibility in solution: a new method for the study of complex distributions of rapidly exchanging conformations. Application to a 13-residue peptide with an 8-residue loop. J. Am. Chem. Soc. 117:1995;1027-1033.
41. Tian Y., Ramesh C.V., Ma X., Naqvi S., Patel T., Cenizal T., et al. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing antibody 2F5: effects of side-chain modifications and conformational constraints. J. Pept. Res. 59:2002;264-276.
42. Parker C.E., Deterding L.J., Hager-Brown C., Binley J.M., Schülke N., Katinger H., et al. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J. Virol. 75:2001;10911-12001.
43. Sreerama N., Woody R.W. A self-consistent method for the analysis of protein secondary structure from circular dichroism. Anal. Biochem. 209:1993;32-44.
44. Brushweiler R., Blackledge M., Ernst R.R. Multi-conformational peptide dynamics derived from NMR data: a new search algorithm and its application to antamanide. J. Biomol. NMR. 1:1991;3-11.
45. Neuhaus D., Williamson M. The Nuclear Overhauser Effect in Structural and Conformational Analysis. 1989;VCH, New York. pp. 160-181, 312-329.
46. Lu M., Blacklow S.C., Kim P.S. A trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein. Biochemistry. 34:1995;14955-14962.
47. Sattenau Q.J., Zolla-Pazner S., Poignard P. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology. 206:1995;713-717.
48. York J., Follis K.E., Trahey M., Nyambi P.N., Zolla-Pazner S., Nunberg J.H. Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus. J. Virol. 75:2001;2741-2752.
49. Gunasekaran K., Ramakrishnan C., Balaram P. β-Hairpins in proteins revisited: lessons for de novo design. Protein Eng. 10:1997;1131-1141.
50. 4+ target cells is a major mechanism of T cell line adapted HIV-1 neutralization. J. Expt. Med. 186:1997;1287-1298.
51. Atherton E., Sheppard R.C. Solid Phase Peptide Synthesis, A Practical Approach. 1989;IRL Press, Oxford.
52. Altieri A.S., Hinton D.P., Byrd R.A. Association of biomolecular systems via pulsed field gradient NMR self-diffusion measurements. J. Am. Chem. Soc. 117:1995;7566-7567.
53. Schleucher J., Schwendiger M., Sattler M., Schmidt P., Schedletzky O., Glaser S.J., et al. A general enhancement scheme in heteronuclear multidimensional NMR employing pulsed field gradients. J. Biomol. NMR. 4:1994;301-306.
54. Delaglio F., Grzesiek S., Vuister G., Zhu G., Pfeifer J., Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR. 6:1995;277-293.
55. Hwang T.L., Shaka A.J. Water suppression that works. Excitation sculpting using arbitrary waveforms and pulsed field. J. Magn. Reson. 112:1995;275-279.
56. Johnson B.A., Blevins R.A. NMRView: a computer program for the visualization and analysis of NMR data. J. Biomol. NMR. 4:1994;603-614.
57. Omichinski J.G., Pedone P.V., Felsenfeld G., Gronenborn A.M., Clore M.G. The solution structure of a specific GAGA factor-DNA complex reveals a modular binding mode. Nature Struct. Biol. 4:1997;122-132.
58. Kelley L.A., Gardner S.P., Sutcliffe M.J. An automated approach for clustering an ensemble of NMR derived protein structures into conformationally related subfamilies. Protein Eng. 9:1996;1063-1065.
59. Nikiforovich G.V., Prakash O., Gehrig C.A., Hruby V.J. Conformations of the dermenkephalin backbone in DMSO solution by a new approach to the solution conformations of flexible peptides. J. Am. Chem. Soc. 115:1993;3399-3406.